Welcome to our dedicated page for Oncolytics Biotech SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncolytics Biotech, Inc. (ONCY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent for pancreatic, breast, and gastrointestinal cancers. Its filings help investors understand how the company describes its programs, capital plans, and corporate structure.
Oncolytics files a range of documents, including Forms 6-K and 8-K that furnish or report material events and press releases. Recent 6-K reports have included information on the formation and expansion of a Gastrointestinal Tumor Scientific Advisory Board, progress toward pivotal and registration-directed studies in pancreatic, colorectal, and anal cancers, and details of an at-the-market sales agreement used to fund pelareorep’s clinical development and general corporate purposes. A Form 8-K has reported leadership appointments in strategy, operations, and biostatistics intended to support late-stage clinical execution.
Filings also describe corporate and jurisdictional changes, such as the proposed domestication from Alberta, Canada, to the State of Nevada in the United States, the company’s transition from foreign private issuer status to domestic issuer status, and related proxy and registration materials. These documents outline the rationale for reducing regulatory complexity, aligning domicile with U.S.-based operations and shareholders, and improving access to U.S. capital markets.
On Stock Titan, investors can review these SEC filings alongside AI-powered summaries that highlight key points, such as clinical trial plans, financing arrangements, and governance changes. Real-time updates from EDGAR, combined with AI explanations of complex documents like registration statements and current reports, help users quickly understand how ONCY’s regulatory disclosures relate to its immuno-oncology strategy and pelareorep development programs.
Oncolytics Biotech Inc. has completed the first step of its planned two-step redomestication by changing its jurisdiction of incorporation from Alberta to British Columbia, Canada, via a statutory continuance under the ABCA and BCBCA. Shareholders approved the continuance and subsequent U.S. domestication at a special meeting held on January 15, 2026.
All outstanding common shares remain outstanding as common shares of the British Columbia entity, with no change to the company’s name or Nasdaq ticker, which continues as ONCY. The current CUSIP (682310875) and ISIN (CA6823108759) remain in place until the expected second step, when the company plans to domesticate to Nevada on March 31, 2026. Effective April 1, 2026, the CUSIP is expected to change to 68237V103 and the ISIN to US68237V1035 while the stock continues trading on Nasdaq as common stock of a Nevada corporation.
Oncolytics Biotech Inc. reported that two new scientific abstracts featuring its investigational immunotherapy pelareorep have been accepted for presentation at the AACR 2026 Annual Meeting. The data come from the GOBLET study in metastatic pancreatic cancer and the AWARE-1 study in early-stage breast cancer.
GOBLET biomarker analyses suggest that adding pelareorep to atezolizumab and chemotherapy can shift pancreatic tumors toward a more immune-active state, with patients showing immune activation signatures experiencing longer progression-free survival and previously reported higher response rates than with chemotherapy alone. AWARE-1 data show pelareorep can drive coordinated anti-tumor immune responses and tertiary lymphoid structure formation, potentially turning immunologically “cold” breast tumors into more treatment-responsive “hot” tumors, supporting pelareorep as an immune-priming backbone for combination therapies across multiple tumor types.
Oncolytics Biotech Inc. director James T. Parsons reported an open-market purchase of 10,000 common shares of the company. The transaction took place at a price of $1.03 per share, indicating a direct cash investment in the stock. Following this trade, Parsons directly owns 41,849 common shares of Oncolytics Biotech Inc., reflecting an increased personal stake in the company’s equity.
Oncolytics Biotech Inc. chief executive officer Jared Kelly reported an open-market purchase of 5,050 common shares on March 12, 2026 at an average price of $0.96 per share. Following this transaction, he directly owns 114,050 common shares, indicating a modest increase in his personal stake.
Oncolytics Biotech Inc. filed an 8-K to highlight the launch of REO 033, a randomized Phase 2 study in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer. Patients will receive either standard bevacizumab plus FOLFIRI or an experimental combination adding pelareorep, with about 30 patients in each arm.
The primary goal is to measure objective response rate, with progression-free survival, overall survival, safety, and biomarker data as additional endpoints. The trial is sponsored by Oncolytics and led by Dr. Sanjay Goel at Rutgers Cancer Institute of New Jersey, with first sites expected to open soon and preliminary data targeted by the end of 2026.
The filing notes earlier REO 022 data in a similar population, where pelareorep-based therapy showed longer median survival and higher response rates than standard care, and that the pelareorep regimen recently received FDA Fast Track Designation in second-line KRAS-mutant MSS metastatic colorectal cancer.
Oncolytics Biotech Inc. is shifting its development strategy to focus on registrational and registration-enabling studies of its immunotherapy pelareorep in squamous cell anal cancer and metastatic colorectal cancer. The company has concluded enrollment in its GOBLET gastrointestinal cancer study, having obtained sufficient clinical and translational data to guide next steps.
Oncolytics plans a mid-April meeting with the U.S. Food and Drug Administration to align on a single-arm registrational study in second-line and later anal cancer, which it believes could enroll well under 100 patients. To concentrate resources and manage spending, the company will wind down GOBLET by stopping new enrollment in the metastatic pancreatic cancer cohorts at approximately 20 patients per arm while continuing to follow existing participants. Management states it has sufficient cash on hand to execute near-term milestones and expects to avoid immediate material dilution.
Oncolytics Biotech Inc. CEO and director Kelly Jared reported buying additional common shares in the open market. On February 11, 2026, he purchased 5,600 common shares at a weighted average price of $0.836, and on February 12, 2026, he bought 29,500 common shares at a weighted average price of $0.842.
The filing notes these were executed through multiple trades at prices ranging from $0.820 to $0.856. After these transactions, Jared directly owns 109,000 Oncolytics Biotech common shares.
Oncolytics Biotech Inc. filed a Form 4 showing that its Chief Financial Officer, Kirk Look, made an open-market purchase of company stock. On February 12, 2026, he bought 12,000 common shares at a price of $0.842 per share. After this transaction, he directly beneficially owned 287,515 common shares of Oncolytics Biotech. The filing classifies this as a direct ownership position, reflecting additional personal investment by the company’s senior financial officer.
Oncolytics Biotech Inc. director Wayne Pisano reported an open-market purchase of 30,000 common shares of ONCY on February 12, 2026. The shares were bought at a weighted average price of $0.8446 per share, in multiple trades ranging from $0.83 to $0.85.
Following this transaction, Pisano directly holds 492,414 common shares of Oncolytics Biotech Inc. The filing notes that detailed trade-by-trade pricing information is available upon request for investors or regulators who want to review each individual purchase within the reported price range.
Oncolytics Biotech Inc. Chief Medical Officer Thomas Charles Heineman reported an open-market purchase of 12,132 common shares on February 12, 2026 at a price of $0.827 per share. Following this transaction, he directly owns 282,818 Oncolytics Biotech common shares.